Page last updated: 2024-12-06
kelevan
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 20226 |
| CHEBI ID | 82101 |
| SCHEMBL ID | 118165 |
| MeSH ID | M0041281 |
Synonyms (27)
| Synonym |
|---|
| despirol |
| general chemical 9160 |
| kelevan |
| allied gc 9160 |
| ai3-27154 |
| kelevan [iso] |
| 1,3,4-metheno-1h-cyclobuta(c,d)-pentalene-2-levulinic acid, 1,1a,3,3a,4,5,5a,5b,6-decachlorooctahydro-2-hydroxy-, ethyl ester |
| general chemicals 9160 |
| caswell no. 436c |
| gc 9160 |
| 1,3,4-methano-1h-cyclobuta(cd)pentalene-2-pentanoic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-gamma-oxo-, ethyl ester |
| ethyl 1,1a,3,3a,4,5,5a,5b,6-decachlorooctahydro-2-hydroxy-1,3,4-metheno-2h-cyclobuta(cd) pentamethylene-2-levulinate |
| C18962 |
| 4234-79-1 |
| elevat |
| 1,3,4-metheno-1h-cyclobuta(cd)pentalene-2-pentanoic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-gamma-oxo-, ethyl ester |
| gc-9160 |
| SCHEMBL118165 |
| CHEBI:82101 |
| DTXSID7058098 |
| 1,3,4-metheno-1h-cyclobuta[cd]pentalene-2-levulinic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-, ethyl ester |
| POSKOXIJDWDKPH-UHFFFAOYSA-N |
| 1,3,4-metheno-1h-cyclobuta[cd]pentalene-2-pentanoic acid, 1,1a,3,3a,4,5,5,5a,5b,6-decachlorooctahydro-2-hydroxy-.gamma.-oxo-, ethyl ester |
| kelevan, pestanal(r), analytical standard |
| Q21042454 |
| ethyl 5-(1,2,3,4,6,7,8,9,10,10-decachloro-5-hydroxy-5-pentacyclo[5.3.0.02,6.03,9.04,8]decanyl)-4-oxopentanoate |
| AKOS040744563 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| oxo carboxylic acid | Any compound that has an aldehydic or ketonic group as well as a carboxylic acid group in the same molecule. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 6 (85.71) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 25.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (25.42) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||